ArticleClinical & developmental immunology2011
Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice.
Article in Clinical & developmental immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era.Frontiers in medicine · 2021Pooled it
- The Role of gp130 Cytokines in Tuberculosis.Cells · 2020Review
- Article
- Host-directed therapies for bacterial and viral infections.Nature reviews. Drug discovery · 2018Review
- Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.Frontiers in cellular and infection microbiology · 2018Review
- Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis.Human vaccines & immunotherapeutics · 2017Article
- Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.BMC medicine · 2016Review
- Modeling Granulomas in Response to Infection in the Lung.PloS one · 2016Article
- The use of Mycobacterium tuberculosis HspX and GlcB proteins to identify latent tuberculosis in rheumatoid arthritis patients.Memorias do Instituto Oswaldo Cruz · 2014Article
- Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.Nature reviews. Rheumatology · 2013Review
- FcγR-driven release of IL-6 by macrophages requires NOX2-dependent production of reactive oxygen species.The Journal of biological chemistry · 2013Article
- Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection.Infection and immunity · 2013Article
- An elucidation of neutrophil functions against Mycobacterium tuberculosis infection.Clinical & developmental immunology · 2013Article
- Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2012Article
- Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.International journal of rheumatology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective. Our aim was to investigate the effects of IL-6 blockade on the progression of Mycobacterium tuberculosis (TB) and compare them with those of TNF-α blockade in mice. Methods. Mice were intravenously infected with TB and injected with antibodies. Survival was monitored and histological and immunological studies were carried out. Results. All anti-IL-6R Ab-treated mice and 8 of 10 control mice survived until sacrificed 224 days after TB challenge, whereas anti-TNF-α Ab-treated mice all died between 120 and 181 days. Anti-IL-6R Ab-treated mice exhibited no significant differences in TB CFU in organs, including the lungs, and no deterioration in histopathology compared to control mice at 4 weeks. In contrast, anti-TNF-α Ab-treated mice exhibited increased TB CFU and greater progression of histopathological findings in organs than control mice. Spleen cells from anti-TNF-α Ab-treated mice had decreased antigen-specific response in IFN-γ release and proliferation assays. The results in anti-IL-6R Ab-treated mice suggest that spleen cell responses were decreased to a lesser degree. Similar results were obtained in IL-6 knockout (KO) mice, compared with TNF receptor 1 (TNFR1) KO and TNFR1/IL-6 double KO (DKO) mice. Conclusion. IL-6R blockade promotes the progression of TB infection in mice far less than TNF-α blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.